IL130897A0 - Atropisomers of 3-heteroaryl-4 (3H)-quinazolinones for the treatment of neurodegenerative and cns-trauma related conditions - Google Patents
Atropisomers of 3-heteroaryl-4 (3H)-quinazolinones for the treatment of neurodegenerative and cns-trauma related conditionsInfo
- Publication number
- IL130897A0 IL130897A0 IL13089798A IL13089798A IL130897A0 IL 130897 A0 IL130897 A0 IL 130897A0 IL 13089798 A IL13089798 A IL 13089798A IL 13089798 A IL13089798 A IL 13089798A IL 130897 A0 IL130897 A0 IL 130897A0
- Authority
- IL
- Israel
- Prior art keywords
- quinazolinones
- atropisomers
- neurodegenerative
- cns
- heteroaryl
- Prior art date
Links
- AVRPFRMDMNDIDH-UHFFFAOYSA-N 1h-quinazolin-2-one Chemical class C1=CC=CC2=NC(O)=NC=C21 AVRPFRMDMNDIDH-UHFFFAOYSA-N 0.000 title 1
- 208000014674 injury Diseases 0.000 title 1
- 230000000626 neurodegenerative effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3854097P | 1997-02-28 | 1997-02-28 | |
| PCT/IB1998/000151 WO1998038187A1 (en) | 1997-02-28 | 1998-02-06 | Atropisomers of 3-heteroaryl-4(3h)-quinazolinones for the treatment of neurodegenerative and cns-trauma related conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL130897A0 true IL130897A0 (en) | 2001-01-28 |
Family
ID=21900535
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL13089798A IL130897A0 (en) | 1997-02-28 | 1998-02-06 | Atropisomers of 3-heteroaryl-4 (3H)-quinazolinones for the treatment of neurodegenerative and cns-trauma related conditions |
Country Status (40)
| Country | Link |
|---|---|
| US (1) | US6380204B1 (zh) |
| EP (1) | EP0964860B1 (zh) |
| JP (1) | JP3299990B2 (zh) |
| KR (1) | KR20000075812A (zh) |
| CN (1) | CN1248254A (zh) |
| AP (1) | AP9801202A0 (zh) |
| AR (1) | AR011886A1 (zh) |
| AT (1) | ATE264854T1 (zh) |
| AU (1) | AU732448B2 (zh) |
| BG (1) | BG103687A (zh) |
| BR (1) | BR9807807A (zh) |
| CA (1) | CA2282279C (zh) |
| CO (1) | CO4950615A1 (zh) |
| DE (1) | DE69823339T2 (zh) |
| DK (1) | DK0964860T3 (zh) |
| DZ (1) | DZ2438A1 (zh) |
| EA (1) | EA001961B1 (zh) |
| ES (1) | ES2218801T3 (zh) |
| GT (1) | GT199800039A (zh) |
| HN (1) | HN1998000028A (zh) |
| HR (1) | HRP980108B1 (zh) |
| HU (1) | HUP0000935A3 (zh) |
| ID (1) | ID23435A (zh) |
| IL (1) | IL130897A0 (zh) |
| IS (1) | IS5141A (zh) |
| MA (1) | MA24485A1 (zh) |
| NO (1) | NO994178L (zh) |
| NZ (1) | NZ336627A (zh) |
| OA (1) | OA11088A (zh) |
| PA (1) | PA8446901A1 (zh) |
| PE (1) | PE57999A1 (zh) |
| PL (1) | PL335307A1 (zh) |
| PT (1) | PT964860E (zh) |
| SK (1) | SK113199A3 (zh) |
| TN (1) | TNSN98034A1 (zh) |
| TR (1) | TR199902094T2 (zh) |
| TW (1) | TW530055B (zh) |
| UA (1) | UA58536C2 (zh) |
| WO (1) | WO1998038187A1 (zh) |
| ZA (1) | ZA981665B (zh) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6323208B1 (en) * | 1997-09-05 | 2001-11-27 | Pfizer Inc | Atropisomers of 2,3-disubstituted-(5.6)-heteroaryl fused-pyrimidin-4-ones |
| JPH11279158A (ja) * | 1998-02-09 | 1999-10-12 | Pfizer Prod Inc | キナゾリン―４―オン誘導体の製造方法 |
| US6890930B1 (en) * | 1999-09-28 | 2005-05-10 | 3-Dimensional Pharmaceuticals, Inc. | Quinazolinones |
| US20080146562A1 (en) * | 2003-08-08 | 2008-06-19 | Ulysses Pharmaceutical Products Inc., | Halogenated quinazolinyl nitrofurans as antibacterial agents |
| AU2004262533A1 (en) * | 2003-08-08 | 2005-02-17 | Ulysses Pharmaceutical Products Inc. | Halogenated quinazolinyl nitrofurans as antibacterial agents |
| GB0416730D0 (en) | 2004-07-27 | 2004-09-01 | Novartis Ag | Organic compounds |
| GB0507298D0 (en) | 2005-04-11 | 2005-05-18 | Novartis Ag | Organic compounds |
| WO2007056124A2 (en) * | 2005-11-04 | 2007-05-18 | Hydra Biosciences, Inc. | Compounds for modulating trpv3 function |
| MX2009003673A (es) * | 2006-10-04 | 2009-04-22 | Pfizer Prod Inc | Derivados de piridido[4,3-d]pirimidin-4(3h)-ona como antagonistas de los receptores de calcio. |
| WO2008140750A1 (en) * | 2007-05-10 | 2008-11-20 | Hydra Biosciences Inc. | Compounds for modulating trpv3 function |
| MX2011009955A (es) * | 2009-03-24 | 2011-11-18 | Gilead Calistoga Llc | Atropisomeros de derivados de 2-purinil-3-tolil-quinazolinona y metodos de uso. |
| EP2435048B1 (en) * | 2009-05-29 | 2019-07-03 | Merck Sharp & Dohme Corp. | Radiolabeled pde10 inhibitors |
| US9216177B2 (en) | 2011-02-28 | 2015-12-22 | Drexel University | Small molecular inhibitors of RAD51 recombinase and methods thereof |
| AU2021212754A1 (en) | 2020-01-29 | 2022-08-04 | Kamari Pharma Ltd. | Compounds and compositions for use in treating skin disorders |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3748325A (en) | 1970-04-06 | 1973-07-24 | Karamchand Premchand Private | Process for the preparation of quinazolinone derivatives |
| US4183931A (en) * | 1977-09-08 | 1980-01-15 | Research Corporation | 2-Ketoalkyl-4(3H)-quinazolinones |
| WO1992013535A1 (en) | 1991-02-06 | 1992-08-20 | Research Corporation Technologies, Inc. | Anticonvulsant substituted quinazolones |
| PT901487E (pt) * | 1996-05-15 | 2003-08-29 | Pfizer | 4(3h)-quinazolinonas 2,3,6-trissubstituidas |
| EP0807633B1 (en) * | 1996-05-15 | 2002-11-06 | Pfizer Inc. | Novel 2,3-disubstituted-(5,6)- heteroarylfused-pyrimidine-4-ones |
-
1998
- 1998-02-06 DE DE69823339T patent/DE69823339T2/de not_active Expired - Fee Related
- 1998-02-06 AT AT98901424T patent/ATE264854T1/de not_active IP Right Cessation
- 1998-02-06 PL PL98335307A patent/PL335307A1/xx unknown
- 1998-02-06 KR KR1019997007885A patent/KR20000075812A/ko active IP Right Grant
- 1998-02-06 EP EP98901424A patent/EP0964860B1/en not_active Expired - Lifetime
- 1998-02-06 TR TR1999/02094T patent/TR199902094T2/xx unknown
- 1998-02-06 HU HU0000935A patent/HUP0000935A3/hu unknown
- 1998-02-06 JP JP53744998A patent/JP3299990B2/ja not_active Expired - Fee Related
- 1998-02-06 US US09/380,114 patent/US6380204B1/en not_active Expired - Fee Related
- 1998-02-06 IL IL13089798A patent/IL130897A0/xx unknown
- 1998-02-06 DK DK98901424T patent/DK0964860T3/da active
- 1998-02-06 BR BR9807807-0A patent/BR9807807A/pt not_active Application Discontinuation
- 1998-02-06 PT PT98901424T patent/PT964860E/pt unknown
- 1998-02-06 ES ES98901424T patent/ES2218801T3/es not_active Expired - Lifetime
- 1998-02-06 ID IDW990935D patent/ID23435A/id unknown
- 1998-02-06 SK SK1131-99A patent/SK113199A3/sk unknown
- 1998-02-06 CN CN98802796A patent/CN1248254A/zh active Pending
- 1998-02-06 NZ NZ336627A patent/NZ336627A/xx unknown
- 1998-02-06 CA CA002282279A patent/CA2282279C/en not_active Expired - Fee Related
- 1998-02-06 WO PCT/IB1998/000151 patent/WO1998038187A1/en not_active Application Discontinuation
- 1998-02-06 AU AU57759/98A patent/AU732448B2/en not_active Ceased
- 1998-02-06 EA EA199900689A patent/EA001961B1/ru not_active IP Right Cessation
- 1998-02-09 HN HN1998000028A patent/HN1998000028A/es unknown
- 1998-02-17 PA PA19988446901A patent/PA8446901A1/es unknown
- 1998-02-19 GT GT199800039A patent/GT199800039A/es unknown
- 1998-02-23 PE PE1998000127A patent/PE57999A1/es not_active Application Discontinuation
- 1998-02-25 DZ DZ980048A patent/DZ2438A1/xx active
- 1998-02-25 TN TNTNSN98034A patent/TNSN98034A1/fr unknown
- 1998-02-25 CO CO98010303A patent/CO4950615A1/es unknown
- 1998-02-25 TW TW087102713A patent/TW530055B/zh not_active IP Right Cessation
- 1998-02-25 MA MA24979A patent/MA24485A1/fr unknown
- 1998-02-26 AR ARP980100872A patent/AR011886A1/es unknown
- 1998-02-26 AP APAP/P/1998/001202A patent/AP9801202A0/en unknown
- 1998-02-27 HR HR980108A patent/HRP980108B1/xx not_active IP Right Cessation
- 1998-02-27 ZA ZA9801665A patent/ZA981665B/xx unknown
- 1998-06-02 UA UA99084850A patent/UA58536C2/uk unknown
-
1999
- 1999-07-30 IS IS5141A patent/IS5141A/is unknown
- 1999-08-20 OA OA9900186A patent/OA11088A/fr unknown
- 1999-08-24 BG BG103687A patent/BG103687A/xx unknown
- 1999-08-27 NO NO994178A patent/NO994178L/no unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL130900A0 (en) | Atropisomers of 3-aryl-4(3H)- quinazolinones and their use as ampa-receptor antagonsts | |
| GB0015235D0 (en) | Compositions for the treatment of skin and anorectal conditions | |
| IL127664A (en) | Compositions for the treatment and prevention of cachexia | |
| IL134718A0 (en) | Treatment of conduct disorder | |
| AP9801414A0 (en) | Combination effective for the treatment of impotence | |
| IL130897A0 (en) | Atropisomers of 3-heteroaryl-4 (3H)-quinazolinones for the treatment of neurodegenerative and cns-trauma related conditions | |
| IL136110A0 (en) | Methods and compositions for the treatment of psoriasis | |
| AU6435398A (en) | Prevention and treatment of hepatocellular cancer | |
| AU1556497A (en) | Agents for the treatment and prevention of aids | |
| AU2476200A (en) | Ribozyme therapy for the treatment and/or prevention of restenosis | |
| GB9808936D0 (en) | Combination therapy for the prevention and treatment of osteoporosis | |
| AU7105498A (en) | Combination therapy for the prevention and treatment of osteoporosis | |
| HUP9700661A3 (en) | Use of alpha-1-adrenoreceptor antagonists for the production of pharmaceuticals for profilacting and treating cancer | |
| AU2663300A (en) | Use of 5-ht5-ligands in the treatment of neurodegenerative and neuropsychiatric disturbances | |
| EP0733365A3 (en) | Use of benzoquinolin-3-one for the treatment and prevention of prostate cancer | |
| HUP0100365A3 (en) | Combination therapy for the treatment of aids | |
| GB9726223D0 (en) | The treatment of materials | |
| KR100248098B1 (en) | Pharmaceutical composition for the treatment of dementia | |
| EP1143998A4 (en) | TREATMENT OF HYPERTENSION | |
| GB9713581D0 (en) | Treatment of neuropsychiatric disorders | |
| GB9821610D0 (en) | Treatment of neuropsychiatric disorders | |
| ZA9810306B (en) | Combination therapy for the treatment of aids | |
| IL121227A0 (en) | Composition for the treatment of seborrhea | |
| GB9923551D0 (en) | Treatment of neuropsychiatric disorders | |
| ZA9811524B (en) | Treatment of effluent |